TY - JOUR
T1 - Berdazimer gel for molluscum contagiosum
T2 - An integrated analysis of 3 randomized controlled trials
AU - Sugarman, Jeffrey L.
AU - Hebert, Adelaide
AU - Browning, John C.
AU - Paller, Amy S.
AU - Stripling, Stephen
AU - Green, Lawrence J.
AU - Cartwright, Martina
AU - Enloe, Carolyn
AU - Wells, Nick
AU - Maeda-Chubachi, Tomoko
N1 - Publisher Copyright:
© 2023 American Academy of Dermatology, Inc.
PY - 2024/2
Y1 - 2024/2
N2 - Background: An out-of-office therapeutic agent indicated for molluscum contagiosum is needed. Objective: To assess the efficacy and safety of berdazimer gel, 10.3% (a topical, antiviral, nitric oxide–releasing medication) versus vehicle. Methods: Berdazimer gel, 10.3% or vehicle was applied once daily to all molluscum contagiosum lesions for 12 weeks in patients ≥6 months with 3-70 mollusca. Efficacy assessment: complete lesion clearance and partial clearance at week 12. Safety and tolerability assessment: adverse events through week 24 and local skin reactions through week 12. Results: There were 1598 patients enrolled (n = 917 berdazimer, n = 681 vehicle). Berdazimer was superior to vehicle at week 12 in complete clearance rates, 30.0% versus 19.8% (odds ratio, 1.75; 95% CI, 1.38-2.23, P < .001). Subgroup analyses of primary efficacy showed consistent favorable efficacy for berdazimer across most subgroups, including age, sex, baseline lesion count, and disease duration. Berdazimer provided favorable outcome for partial clearance. Application-site pain (18.7% vs 4.8% in berdazimer vs vehicle) and erythema (11.7% vs 1.3%), mostly mild to moderate, were the most common local skin reactions. Limitations: Berdazimer sodium in molluscum patients with lesions (B-SIMPLE) trials enrolled only US patients; no efficacy assessments beyond week 12. Conclusions: Berdazimer gel, 10.3% showed favorable efficacy and safety across subgroups.
AB - Background: An out-of-office therapeutic agent indicated for molluscum contagiosum is needed. Objective: To assess the efficacy and safety of berdazimer gel, 10.3% (a topical, antiviral, nitric oxide–releasing medication) versus vehicle. Methods: Berdazimer gel, 10.3% or vehicle was applied once daily to all molluscum contagiosum lesions for 12 weeks in patients ≥6 months with 3-70 mollusca. Efficacy assessment: complete lesion clearance and partial clearance at week 12. Safety and tolerability assessment: adverse events through week 24 and local skin reactions through week 12. Results: There were 1598 patients enrolled (n = 917 berdazimer, n = 681 vehicle). Berdazimer was superior to vehicle at week 12 in complete clearance rates, 30.0% versus 19.8% (odds ratio, 1.75; 95% CI, 1.38-2.23, P < .001). Subgroup analyses of primary efficacy showed consistent favorable efficacy for berdazimer across most subgroups, including age, sex, baseline lesion count, and disease duration. Berdazimer provided favorable outcome for partial clearance. Application-site pain (18.7% vs 4.8% in berdazimer vs vehicle) and erythema (11.7% vs 1.3%), mostly mild to moderate, were the most common local skin reactions. Limitations: Berdazimer sodium in molluscum patients with lesions (B-SIMPLE) trials enrolled only US patients; no efficacy assessments beyond week 12. Conclusions: Berdazimer gel, 10.3% showed favorable efficacy and safety across subgroups.
KW - berdazimer
KW - dermatology
KW - molluscum contagiosum
KW - nitric oxide
KW - pediatrics
KW - topical administration
UR - http://www.scopus.com/inward/record.url?scp=85175298402&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85175298402&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2023.09.066
DO - 10.1016/j.jaad.2023.09.066
M3 - Article
C2 - 37804936
AN - SCOPUS:85175298402
SN - 0190-9622
VL - 90
SP - 299
EP - 308
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 2
ER -